IcoSema: unveiling the future of diabetes management from a clinical pharmacology perspective.

Q3 Pharmacology, Toxicology and Pharmaceutics Journal of Basic and Clinical Physiology and Pharmacology Pub Date : 2024-06-11 eCollection Date: 2024-07-01 DOI:10.1515/jbcpp-2024-0058

Rajmohan Seetharaman, Rhea Monteiro, Jay Maradia, Raakhi Tripathi

{"title":"IcoSema: unveiling the future of diabetes management from a clinical pharmacology perspective.","authors":"Rajmohan Seetharaman, Rhea Monteiro, Jay Maradia, Raakhi Tripathi","doi":"10.1515/jbcpp-2024-0058","DOIUrl":null,"url":null,"abstract":"<p><p>IcoSema, a groundbreaking approach to diabetes management, combines insulin icodec and semaglutide to offer a transformative treatment option. Insulin icodec delivers consistent glucose-lowering effects with once-weekly dosing, while semaglutide, a GLP-1 agonist, stimulates insulin secretion and aids in weight loss. This comprehensive article evaluates the potential of IcoSema from a clinical pharmacology perspective, examining the pharmacokinetics, efficacy, safety, compliance and cost-effectiveness of its individual components, as well as considering comparable combination therapies like iGlarLixi and IDegLira. By analysing these crucial factors, the article aims to determine the potential of IcoSema in the field of diabetes management. The combination of insulin icodec and semaglutide has the potential to provide improved glycaemic control, weight management, and simplified treatment regimens, addressing common challenges faced in diabetes management. Safety, compliance and cost considerations are important aspects of evaluating this combination therapy. Ongoing trials investigating IcoSema are expected to provide valuable insights into its efficacy, safety and comparative effectiveness. By addressing concerns such as potential side effects, individual patient response and drug interactions, healthcare providers can optimize treatment outcomes and enhance the management of type 2 diabetes.</p>","PeriodicalId":15352,"journal":{"name":"Journal of Basic and Clinical Physiology and Pharmacology","volume":" ","pages":"213-224"},"PeriodicalIF":0.0000,"publicationDate":"2024-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Basic and Clinical Physiology and Pharmacology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1515/jbcpp-2024-0058","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}

引用次数: 0

Abstract

IcoSema, a groundbreaking approach to diabetes management, combines insulin icodec and semaglutide to offer a transformative treatment option. Insulin icodec delivers consistent glucose-lowering effects with once-weekly dosing, while semaglutide, a GLP-1 agonist, stimulates insulin secretion and aids in weight loss. This comprehensive article evaluates the potential of IcoSema from a clinical pharmacology perspective, examining the pharmacokinetics, efficacy, safety, compliance and cost-effectiveness of its individual components, as well as considering comparable combination therapies like iGlarLixi and IDegLira. By analysing these crucial factors, the article aims to determine the potential of IcoSema in the field of diabetes management. The combination of insulin icodec and semaglutide has the potential to provide improved glycaemic control, weight management, and simplified treatment regimens, addressing common challenges faced in diabetes management. Safety, compliance and cost considerations are important aspects of evaluating this combination therapy. Ongoing trials investigating IcoSema are expected to provide valuable insights into its efficacy, safety and comparative effectiveness. By addressing concerns such as potential side effects, individual patient response and drug interactions, healthcare providers can optimize treatment outcomes and enhance the management of type 2 diabetes.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

IcoSema：从临床药理学角度揭示糖尿病管理的未来。

IcoSema 是一种开创性的糖尿病治疗方法，它将胰岛素 icodec 和 semaglutide 结合在一起，提供了一种变革性的治疗选择。胰岛素 icodec 每周用药一次，具有持续的降糖效果，而 GLP-1 激动剂 semaglutide 可刺激胰岛素分泌并帮助减轻体重。这篇综合性文章从临床药理学的角度评估了 IcoSema 的潜力，研究了其单个成分的药代动力学、疗效、安全性、依从性和成本效益，并考虑了 iGlarLixi 和 IDegLira 等同类组合疗法。通过分析这些关键因素，文章旨在确定 IcoSema 在糖尿病管理领域的潜力。伊科赛马胰岛素和塞马鲁肽的组合有望改善血糖控制、体重管理和简化治疗方案，解决糖尿病管理中面临的共同挑战。安全性、依从性和成本因素是评估这种联合疗法的重要方面。目前正在进行的 IcoSema 试验有望在疗效、安全性和比较效果方面提供有价值的见解。通过解决潜在副作用、患者个体反应和药物相互作用等问题，医疗服务提供者可以优化治疗效果，加强对 2 型糖尿病的管理。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Journal of Basic and Clinical Physiology and Pharmacology Pharmacology, Toxicology and Pharmaceutics-Pharmacology

CiteScore

3.90

自引率

0.00%

发文量

期刊介绍： The Journal of Basic and Clinical Physiology and Pharmacology (JBCPP) is a peer-reviewed bi-monthly published journal in experimental medicine. JBCPP publishes novel research in the physiological and pharmacological sciences, including brain research; cardiovascular-pulmonary interactions; exercise; thermal control; haematology; immune response; inflammation; metabolism; oxidative stress; and phytotherapy. As the borders between physiology, pharmacology and biochemistry become increasingly blurred, we also welcome papers using cutting-edge techniques in cellular and/or molecular biology to link descriptive or behavioral studies with cellular and molecular mechanisms underlying the integrative processes. Topics: Behavior and Neuroprotection, Reproduction, Genotoxicity and Cytotoxicity, Vascular Conditions, Cardiovascular Function, Cardiovascular-Pulmonary Interactions, Oxidative Stress, Metabolism, Immune Response, Hematological Profile, Inflammation, Infection, Phytotherapy.